Google
ZLAB — ZAI LAB LTD (Healthcare >> Biotechnology)
ZLAB FAQ
What is ZLAB's ROE?
ZAI LAB LTD reports a Return on Equity (ROE) of -26.91%.
What is ZLAB's dividend yield?
ZAI LAB LTD offers a dividend yield of 0.00%.
What is ZLAB's Deepscope Quality Score?
Deepscope rates ZLAB's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ZLAB?
Deepscope's AI Timing Score for ZLAB is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ZLAB belong to?
ZAI LAB LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 16.48
Price
0.17
(1.03%)
Day Change
|
|
|---|
ZLAB, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 77 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 16.48 |
| PBV / Sector |
2.81 / 4.75
|
| Earning Per Share | -1.58 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
16.49 M
GREAT
|
| Average 1W Daily Value |
18.07 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-09 09:40:15 |
| Symbol | ZLAB |
| Name | ZAI LAB LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 112.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,860.03 / 9,000.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building B, Pudong, China, 201203
Phone: 86 21 6163 2588
Website: https://www.zailaboratory.com
Employees: 1,784
Sector: Healthcare >> Biotechnology
Description: Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
